(1S,9S)-4-methoxy-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: (1S,9S)-4-methoxy-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene
• 化学式: C₁₇H₂₃NO
• 分子量: 257.376
• InChiKey: ILNSWVUXAPSPEH-HGVHAKBWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  dextromethorphan 在 DAP⁽²⁺⁾*2BF₄⁽¹⁺⁾ 、 氧气 作用下， 以 乙腈 为溶剂， 反应 2.0h， 以95%的产率得到(1S,9S)-4-methoxy-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene
  参考文献：
  名称：

  Electron-transfer activation. Photochemical N-demethylation of tertiary amines

  摘要：

  DOI：

  10.1016/s0040-4039(00)99160-3

文献信息

• Methods for treating depressive symptoms
  申请人：Alkermes Pharma Ireland Limited

  公开号：US10231963B2

  公开（公告）日：2019-03-19

  The present application relates methods for treating a depressive symptom comprising administering an effective amount of a μ opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof. Non-limiting examples of such agonist include the compounds of Formulas I, II, III, and IV, as well as the compounds of Table A.

  本申请涉及治疗抑郁症状的方法，包括向有需要的受试者施用有效量的μ阿片受体激动剂或其药学上可接受的盐。此类激动剂的非限制性实例包括式I、II、III和IV化合物以及表A化合物。
• Morphan and morphinan analogues, and methods of use
  申请人：Alkermes Pharma Ireland Limited

  公开号：US10287250B2

  公开（公告）日：2019-05-14

  The present application relates to analogs of morphan and morphinan, compositions thereof, and methods for treating a disease or condition comprising administering an effective amount of the compounds or compositions to a subject in need thereof.

  本申请涉及吗啡烷和吗啡烷的类似物、其组合物以及治疗疾病或病症的方法，其中包括向有需要的受试者施用有效量的化合物或组合物。
• LOCAL ANESTHETIC COMPOSITIONS CONTAINING DEXTROROTATORY MORPHINAN DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
  申请人：WANG JHI-JOUNG

  公开号：US20080070939A1

  公开（公告）日：2008-03-20

  Dextrorotatory morphinan derivatives of formula (I) or pharmaceutically acceptable salts thereof were found to have local anesthetic effects: wherein R and R′ are independently selected from hydrogen and a methyl group, and at least one of R and R′ is a methyl group. The dextrorotatory morphinan derivatives of formula (I) or pharmaceutically acceptable salts thereof can therefore be used in the manufacture of pharmaceutical compositions for local anesthesia that may provide a safe and prolonged local anesthetic effect.
• METHODS FOR TREATING DEPRESSIVE SYMPTOMS
  申请人：Alkermes Pharma Ireland Limited

  公开号：US20170216279A1

  公开（公告）日：2017-08-03

  The present application relates methods for treating a depressive symptom comprising administering an effective amount of a μ opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof. Non-limiting examples of such agonist include the compounds of Formulas I, II, III, and IV, as well as the compounds of Table A.
• Morphan And Morphinan Analogues, And Methods Of Use
  申请人：Alkermes Pharma Ireland Limited

  公开号：US20180016237A1

  公开（公告）日：2018-01-18

  The present application relates to analogues of morphan and morphinan, compositions thereof, and methods for treating a disease or condition comprising administering an effective amount of the compounds or compositions to a subject in need thereof.